Filing Details

Accession Number:
0001127602-23-010081
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-14 16:18:24
Reporting Period:
2023-03-13
Accepted Time:
2023-03-14 16:18:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1665678 Charles Alpuche C/O Insulet Corporation
100 Nagog Park
Acton MA 01720
Advisor No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-13 23,401 $31.21 68,985 No 4 M Direct
Common Stock Disposition 2023-03-13 23,401 $305.15 45,584 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2023-03-13 23,401 $0.00 23,401 $31.21
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,347 2026-02-03 No 4 M Direct
Footnotes
  1. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $302.98 to $307.17. Specifically: 8,975 shares were sold in the range of $302.98 to $303.98, with a weighted average share price of $303.60; 1,100 shares were sold in the range of $304.01 to $304.29, with a weighted average share price of $304.08; 7,524 shares were sold in the range of $305.35 to $306.35, with a weighted average share price of $305.94;
  2. Footnote continued: and 5802 shares were sold in the range of $306.41 to $307.17, with a weighted average share price of $306.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  3. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.